Big Move For Sophiris Bio, Inc.
Mon 27 Jan 20 at 05:30 PM
Sophiris Bio, Inc. (SPHS:NASDAQ) rocketted at $0.86, representing a gain of 27.2%. From Fri 03 Jan 20, the stock recorded 35.71% Up Days and 46.67% Green Days
About Sophiris Bio, Inc. (SPHS:NASDAQ)
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. The Company is engaged in research and development of products for the treatment of urological diseases. It is currently developing PRX302 for treatment of benign prostatic hyperplasia.
Top 10 Gainers:
- Cleveland BioLabs, Inc. (CBLI:NASDAQ), 210.61%
- Lianluo Smart Limited (LLIT:NASDAQ), 152.29%
- NanoViricides, Inc. (NNVC:NYSEMKT), 86.98%
- Co-Diagnostics, Inc. (CODX:NASDAQ), 82.45%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 65.42%
- Miragen Therapeutics, Inc. (MGEN:NASDAQ), 50.52%
- Allied Healthcare Products, Inc. (AHPI:NASDAQ), 50%
- Vaxart, Inc. (VXRT:NASDAQ), 30%
- Alpha Pro Tech, Ltd. (APT:NYSEMKT), 28.33%
- Sophiris Bio, Inc. (SPHS:NASDAQ), 27.23%